mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-6-98-106mrj-1673Research ArticleОБЗОРЫREVIEWSБиоаналоги в лечении ревматоидного артрита: современное состояние проблемыBioanalogues in the treatment of rheumatoid arthritis: current status of the problemhttps://orcid.org/0000-0001-8051-8659ЧичасоваН. В.ChichasovaN. V.

Наталья Владимировна Чичасова

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

Natalia Vladimirovna Chichasova

34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993

kafedrarheum@yandex.ruhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation20241412202418698106Copyright © Чичасова Н.В., Лила А.М., 20242024Чичасова Н.В., Лила А.М.Chichasova N.V., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1673

В статье обсуждаются вопросы применения биоаналогов (БА) в лечении ревматоидного артрита на примере сопоставимой эффективности, переносимости, иммуногенности оригинального генно-инженерного биологического препарата (ГИБП) этанерцепта (ЭТЦ) и его БА GP2015, а также сохранение достигнутого улучшения при переключении с оригинального ЭТЦ на БА. Приведены рекомендации международных экспертов и предварительные рекомендации Ассоциации ревматологов России по применению БА. Описаны частота развития и негативные последствия эффекта ноцебо при переводе больных на БА. Представлены данные рандомизированных контролируемых исследований и клинической практики о безопасности перевода больных с оригинальных ГИБП на БА. Рассмотрены экономические преимущества внедрения БА в клиническую практику ревматологов стран Европы и Российской Федерации.

The article discusses the use of bioanalogues (BAs) in the treatment of rheumatoid arthritis using the example of the comparable efficacy, tolerability and immunogenicity of the original biologic disease-modifying antirheumatic drug (bDMARD) etanercept (ETC) and its BA GP-2015. We discuss the maintenance of the improvement achieved when switching from the original ETC to BA. Recommendations of international experts and preliminary recommendations of the Association of Rheumatologists of Russia on the use of BA are given. The frequency of development and negative consequences of the nocebo effect when switching patients to BA are described. Data from randomized controlled trials and clinical practice on the safety of switching patients from original biologics to BA are presented. The economic benefits of introducing BA into the clinical practice of rheumatologists in Europe and Russian Federation are considered.

ревматоидный артритгенно-инженерные биологические препаратыэтанерцептбиоаналог GP2015ноцебоrheumatoid arthritisbiologic disease-modifying antirheumatic drugetanerceptbiosimilar GP2015noceboИсследование не имело спонсорской поддержки.The investigation has not been sponsored.ReferencesSmolen JS, Aletaha D, Bijlsma JW, et al. Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9.Smolen JS, Aletaha D, Bijlsma JW, et al. Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9.Smolen JS, Landewe RBM, Bijlsma WJ, et al. EULAR Recommendations for the Management of rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.Smolen JS, Landewe RBM, Bijlsma WJ, et al. EULAR Recommendations for the Management of rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.Nasonov EL, editortor. Russian clinical guidelines. Rheumatology. Moscow: GEOTARMedia; 2020. 448 p.Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8.Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8.Министерство здравоохранения Российской Федерации. Клинические Рекомендации. Ревматоидный артрит. 2023 г.The Ministry of Health of the Russian Federation. Clinical Recommendations. Rheumatoid arthritis. 2023.Yu C, Jin S, Wang Y, et al. Remission Rate and Predictors of Remission in Patients with Rheumatoid Arthritis under Treat-To-Target Strategy in Real-World Studies: A Systematic Review and Meta-Analysis. Clin Rheumatol. 2019 Mar;38(3):727-738. doi: 10.1007/s10067-018-4340-7. Epub 2018 Oct 19.Yu C, Jin S, Wang Y, et al. Remission Rate and Predictors of Remission in Patients with Rheumatoid Arthritis under Treat-To-Target Strategy in Real-World Studies: A Systematic Review and Meta-Analysis. Clin Rheumatol. 2019 Mar;38(3):727-738. doi: 10.1007/s10067-018-4340-7. Epub 2018 Oct 19.Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis. A Review. JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103.Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis. A Review. JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103.Tanaka Y, Yamanaka H, Ishiguro N, et al. Low Disease Activity for Up to 3 Years after Adalimumab Discontinuation in Patients with Early Rheumatoid Arthritis: 2-Year Results of the HOPEFUL-3 Study. Arthritis Res Ther. 2017 Mar 14;19(1):56. doi: 10.1186/s13075-017-1264-6.Tanaka Y, Yamanaka H, Ishiguro N, et al. Low Disease Activity for Up to 3 Years after Adalimumab Discontinuation in Patients with Early Rheumatoid Arthritis: 2-Year Results of the HOPEFUL-3 Study. Arthritis Res Ther. 2017 Mar 14;19(1):56. doi: 10.1186/s13075-017-1264-6.Beayert R, Fiers W. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis AR, Thorpe R, editors. Cytokines. 1st ed. London: Academic Press; 1998. P. 35-60.Beayert R, Fiers W. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis AR, Thorpe R, editors. Cytokines. 1st ed. London: Academic Press; 1998. P. 35-60.Насонов ЕЛ. Фактор некроза опухоли-α – новая мишень для противовоспалительной терапии ревматоидного артрита. Русский медицинский журнал 2000;(17):718-722.Nasonov EL. Tumor necrosis factor-α is a new target for anti–inflammatory therapy of rheumatoid arthritis. Russkii meditsinskii zhurnal 2000;(17):718-722. (In Russ.)Hira K, Begum AS. Methods for Evaluation of TNF-α Inhibition Effect. Methods Mol Biol. 2021:2248:271-279. doi: 10.1007/978-1-0716-1130-2_21.Hira K, Begum AS. Methods for Evaluation of TNF-α Inhibition Effect. Methods Mol Biol. 2021:2248:271-279. doi: 10.1007/978-1-0716-1130-2_21.Насонов ЕЛ. Эффективность и безопасность ингибиторов фактора некроза опухоли-α при ревматоидном артрите. Русский медицинский журнал 2008;(24): 1602-1609.Nasonov EL. Efficacy and safety of tumor necrosis factor-α inhibitors in rheumatoid arthritis. Russkii meditsinskii zhurnal 2008; (24):1602-1609. (In Russ.)Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27.Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27.Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD004525. doi: 10.1002/14651858.CD004525.pub2.Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD004525. doi: 10.1002/14651858.CD004525.pub2.Eng G, Stoltenberg MB, Szkudlarek M. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: A systematic review of cohort studies with focus on dose. Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6.Eng G, Stoltenberg MB, Szkudlarek M. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: A systematic review of cohort studies with focus on dose. Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6.Bucley F, Finckh A, Huizinda TWJ, et al. Comparative efficacy of novel disease-modifying antirheumatic drugs as a monotherapy and in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to traditional DMARDS: a network meta-analysis. J Manag Care Spec Pharm. 2015 May;21(5):409-23. doi: 10.18553/jmcp.2015.21.5.409.Bucley F, Finckh A, Huizinda TWJ, et al. Comparative efficacy of novel disease-modifying antirheumatic drugs as a monotherapy and in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to traditional DMARDS: a network meta-analysis. J Manag Care Spec Pharm. 2015 May;21(5):409-23. doi: 10.18553/jmcp.2015.21.5.409.Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375-82. doi: 10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375-82. doi: 10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.Camean-Castillo M, Gimeno-Ballester V, Rios-Sanchez E, et al. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. J Clin Pharm Ther. 2019 Jun;44(3): 384-396. doi: 10.1111/jcpt.12795Camean-Castillo M, Gimeno-Ballester V, Rios-Sanchez E, et al. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. J Clin Pharm Ther. 2019 Jun;44(3): 384-396. doi: 10.1111/jcpt.12795Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials. National registries and postmarketing surveillance. J Rheumatol Suppl. 2014 May:91:47-55. doi: 10.3899/jrheum.140102.Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials. National registries and postmarketing surveillance. J Rheumatol Suppl. 2014 May:91:47-55. doi: 10.3899/jrheum.140102.Nasonov EL, Kozlov RS, Yakushin SB. In fectious complications of therapy with tumor necrosis factor blockers: warned means armed. Klinicheskaya Mikrobiologiya i antimikrobnaya khimioterapiya. 2006;8(4):314-324. (In Russ.).Nasonov EL, Kozlov RS, Yakushin SB. In fectious complications of therapy with tumor necrosis factor blockers: warned means armed. Klinicheskaya Mikrobiologiya i antimikrobnaya khimioterapiya. 2006;8(4):314-324. (In Russ.).Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The tree-year prospective french research axed tolerance of biotherapy registry. Arthritis Rheum. 2009 Jul;60(7):1884-94. doi: 10.1002/art.24632.Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The tree-year prospective french research axed tolerance of biotherapy registry. Arthritis Rheum. 2009 Jul;60(7):1884-94. doi: 10.1002/art.24632.Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010 Jan;62(1): 22-32. doi: 10.1002/art.27227.Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010 Jan;62(1): 22-32. doi: 10.1002/art.27227.Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1.Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1.Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021 Feb;17(2): 81-97. doi: 10.1038/s41584-020-00540-8. Epub 2020 Dec 14.Strand V, Goncalves J, Isaacs JD. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol. 2021 Feb;17(2): 81-97. doi: 10.1038/s41584-020-00540-8. Epub 2020 Dec 14.Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718. doi: 10.1038/nrrheum.2017.187.Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):707-718. doi: 10.1038/nrrheum.2017.187.Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013 Feb;72(2):165-78. doi: 10.1136/annrheumdis2012-202545. Epub 2012 Nov 24.Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013 Feb;72(2):165-78. doi: 10.1136/annrheumdis2012-202545. Epub 2012 Nov 24.Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017.Moots RJ, Xavier RM, Mok CC, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017.Azevedo VF, Galli N, Kleinfelder F, et al. Etanercept biosimilars. Rheumatol Int. 2015 Feb;35(2):197-209. doi: 10.1007/s00296-014-3080-5. Epub 2014 Jul 1.Azevedo VF, Galli N, Kleinfelder F, et al. Etanercept biosimilars. Rheumatol Int. 2015 Feb;35(2):197-209. doi: 10.1007/s00296-014-3080-5. Epub 2014 Jul 1.European Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdfEuropean Medicines Agency (EMA) (2013) Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdfUS Food and Drug Administration (FDA) (2010) Title VII: improving access to innovative medical therapies. Subtitle A: biologic price competition and innovation (BPCIA) Provisions of the Patient Protection and Affordable Care Act (PPACA). http://www.fda.gov/downloads/Drugs/US Food and Drug Administration (FDA) (2010) Title VII: improving access to innovative medical therapies. Subtitle A: biologic price competition and innovation (BPCIA) Provisions of the Patient Protection and Affordable Care Act (PPACA). http://www.fda.gov/downloads/Drugs/Kay J, Schoels MM, DörnerT, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2.Kay J, Schoels MM, DörnerT, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2.Karateev D, Belokoneva N. Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing. Biomolecules. 2019 Feb 11;9(2):57. doi: 10.3390/biom9020057.Karateev D, Belokoneva N. Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing. Biomolecules. 2019 Feb 11;9(2):57. doi: 10.3390/biom9020057.Von Richter O, Skerjanec A, Alfoso M, et al. A proposed Etanercept biosimilar: pharmokinetic similarity to its reference product and comparison of its auto injector device with prefilled syringes. Br J Clin Pharmacol. 2017 Apr;83(4):732-741. doi: 10.1111/bcp.13170. Epub 2016 Dec 16.Von Richter O, Skerjanec A, Alfoso M, et al. A proposed Etanercept biosimilar: pharmokinetic similarity to its reference product and comparison of its auto injector device with prefilled syringes. Br J Clin Pharmacol. 2017 Apr;83(4):732-741. doi: 10.1111/bcp.13170. Epub 2016 Dec 16.Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, Safety and Immunogenicity of GP2015, an Etanercept Biosimilar, Compared with the Reference Etanercept in Patients with Moderate-To-Severe Rheumatoid Arthritis: 24-Week Results from the Comparative Phase III, Randomised, Double-Blind EQUIRA Study. RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018.Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, Safety and Immunogenicity of GP2015, an Etanercept Biosimilar, Compared with the Reference Etanercept in Patients with Moderate-To-Severe Rheumatoid Arthritis: 24-Week Results from the Comparative Phase III, Randomised, Double-Blind EQUIRA Study. RMD Open. 2018 Nov 14;4(2):e000757. doi: 10.1136/rmdopen-2018-000757. eCollection 2018.Jaworski J, Matucci-Cerinic M, SchulzeKoops H, et al. Switch from Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients with Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results from the Phase III, Randomized, Double-Blind EQUIRA Study. Arthritis Res Ther. 2019 May 28;21(1):130. doi: 10.1186/s13075-019-1907-x.Jaworski J, Matucci-Cerinic M, SchulzeKoops H, et al. Switch from Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients with Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results from the Phase III, Randomized, Double-Blind EQUIRA Study. Arthritis Res Ther. 2019 May 28;21(1):130. doi: 10.1186/s13075-019-1907-x.Colloca L. The Nocebo effect. Annu Rev Pharmacol Toxicol. 2024 Jan 23:64:171-190. doi: 10.1146/annurev-pharmtox-022723-112425. Epub 2023 Aug 16.Colloca L. The Nocebo effect. Annu Rev Pharmacol Toxicol. 2024 Jan 23:64:171-190. doi: 10.1146/annurev-pharmtox-022723-112425. Epub 2023 Aug 16.Peyrin-Biroulet L, Lönnfors S, Roblin X, et al. Patient perspectives on biosimilars: a survey by the European Federation of Crohn’s and Ulcerative Colitis Associations. J Crohns Colitis. 2017 Jan;11(1):128-133. doi: 10.1093/ecco-jcc/jjw138. Epub 2016 Jul 31.Peyrin-Biroulet L, Lönnfors S, Roblin X, et al. Patient perspectives on biosimilars: a survey by the European Federation of Crohn’s and Ulcerative Colitis Associations. J Crohns Colitis. 2017 Jan;11(1):128-133. doi: 10.1093/ecco-jcc/jjw138. Epub 2016 Jul 31.Palermo S, Benedetti F, Costa T, et al. Pain anticipation: an activation likelihood estimation meta-analysis of brain imaging studies. Hum Brain Mapp. 2015 May;36(5): 1648-61. doi: 10.1002/hbm.22727. Epub 2014 Dec 19.Palermo S, Benedetti F, Costa T, et al. Pain anticipation: an activation likelihood estimation meta-analysis of brain imaging studies. Hum Brain Mapp. 2015 May;36(5): 1648-61. doi: 10.1002/hbm.22727. Epub 2014 Dec 19.Carlino E, Benedetti F. Different contexts, different pains, different experiences. Neuroscience. 2016 Dec 3:338:19-26. doi: 10.1016/j.neuroscience.2016.01.053. Epub 2016 Jan 28.Carlino E, Benedetti F. Different contexts, different pains, different experiences. Neuroscience. 2016 Dec 3:338:19-26. doi: 10.1016/j.neuroscience.2016.01.053. Epub 2016 Jan 28.Benedetti F, Lanotte M, Lopiano L, et al. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007 Jun 29;147(2):260-71. doi: 10.1016/j.neuroscience.2007.02.020. Epub 2007 Mar 26.Benedetti F, Lanotte M, Lopiano L, et al. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007 Jun 29;147(2):260-71. doi: 10.1016/j.neuroscience.2007.02.020. Epub 2007 Mar 26.Freeman S, Yu R, Egorova N, et al. Distinct neural representations of placebo and nocebo effects. Neuroimage. 2015 May 15: 112:197-207. doi: 10.1016/j.neuroimage.2015.03.015. Epub 2015 Mar 14.Freeman S, Yu R, Egorova N, et al. Distinct neural representations of placebo and nocebo effects. Neuroimage. 2015 May 15: 112:197-207. doi: 10.1016/j.neuroimage.2015.03.015. Epub 2015 Mar 14.Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CTP13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677-83. doi: 10.1517/14712598.2015.1103733. Epub 2015 Nov 7.Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CTP13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677-83. doi: 10.1517/14712598.2015.1103733. Epub 2015 Nov 7.Abdalla A, Byrne N, Conway R, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Open Access Rheumatol. 2017 Mar 7:9:29-35. doi: 10.2147/OARRR.S124975. eCollection 2017.Abdalla A, Byrne N, Conway R, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Open Access Rheumatol. 2017 Mar 7:9:29-35. doi: 10.2147/OARRR.S124975. eCollection 2017.Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018 Oct;85(5):561-567. doi: 10.1016/j.jbspin.2017.10.003. Epub 2017 Nov 14.Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018 Oct;85(5):561-567. doi: 10.1016/j.jbspin.2017.10.003. Epub 2017 Nov 14.Avouac J, Molto A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018 Apr; 47(5):741-748. doi: 10.1016/j.semarthrit.2017.10.002. Epub 2017 Oct 5.Avouac J, Molto A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018 Apr; 47(5):741-748. doi: 10.1016/j.semarthrit.2017.10.002. Epub 2017 Oct 5.Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018 Jan;70(1):60-68. doi: 10.1002/art.40324. Epub 2017 Dec 7.Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018 Jan;70(1):60-68. doi: 10.1002/art.40324. Epub 2017 Dec 7.Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-month comparative open-label study. J Clin Med. 2019 Jul 2;8(7):956. doi: 10.3390/jcm8070956.Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained clinical remission in ankylosing spondylitis patients switched from reference infliximab to its biosimilar: an 18-month comparative open-label study. J Clin Med. 2019 Jul 2;8(7):956. doi: 10.3390/jcm8070956.Tweehuysen L, Huiskes VJ, van den Bemt BJ, et al. Open-label non-mandatory transitioning from originator etanercept to biosimilar sb4: 6-month results from a controlled cohort study. Arthritis Rheumatol. 2018 Sep;70(9): 1408-1418. doi: 10.1002/art.40516. Epub 2018 Aug 6.Tweehuysen L, Huiskes VJ, van den Bemt BJ, et al. Open-label non-mandatory transitioning from originator etanercept to biosimilar sb4: 6-month results from a controlled cohort study. Arthritis Rheumatol. 2018 Sep;70(9): 1408-1418. doi: 10.1002/art.40516. Epub 2018 Aug 6.Planes S, Villier C, Mallaret M. The noce bo effect of drugs. Pharmacol Res Perspect. 2016 Mar 17;4(2):e00208. doi: 10.1002/prp2.208. eCollection 2016 Apr.Planes S, Villier C, Mallaret M. The noce bo effect of drugs. Pharmacol Res Perspect. 2016 Mar 17;4(2):e00208. doi: 10.1002/prp2.208. eCollection 2016 Apr.Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011 Apr;31(5):550-61. doi: 10.1177/0333102410391485. Epub 2011 Jan 7.Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia. 2011 Apr;31(5):550-61. doi: 10.1177/0333102410391485. Epub 2011 Jan 7.Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012 Mar;259(3):436-47. doi: 10.1007/s00415-011-6197-4. Epub 2011 Aug 3.Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2012 Mar;259(3):436-47. doi: 10.1007/s00415-011-6197-4. Epub 2011 Aug 3.Häuser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int. 2012 Jun;109(26):459-65. doi: 10.3238/ arztebl.2012.0459. Epub 2012 Jun 29.Häuser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int. 2012 Jun;109(26):459-65. doi: 10.3238/arztebl.2012.0459. Epub 2012 Jun 29.Liccardi G, Senna G, Russo M, et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol. 2004;14(2):104-7.Liccardi G, Senna G, Russo M, et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol. 2004;14(2):104-7.Voelker R. Nocebos contribute to host of ills. JAMA. 1996 Feb 7;275(5):345, 347. doi: 10.1001/jama.275.5.345.Voelker R. Nocebos contribute to host of ills. JAMA. 1996 Feb 7;275(5):345, 347. doi: 10.1001/jama.275.5.345.Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002 Feb 6;287(5):622-7. doi: 10.1001/jama.287.5.622.Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002 Feb 6;287(5):622-7. doi: 10.1001/jama.287.5.622.Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014 Jan 30;215(1):82-6. doi: 10.1016/j.psychres.2013.10.019. Epub 2013 Oct 25.Mitsikostas DD, Mantonakis L, Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2014 Jan 30;215(1):82-6. doi: 10.1016/j.psychres.2013.10.019. Epub 2013 Oct 25.Pope J, Hall S, Bombardier C, et al. Postswitch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study. Adv Ther. 2022 Nov;39(11):5259-5273. doi: 10.1007/s12325-022-02303-1. Epub 2022 Sep 22.Pope J, Hall S, Bombardier C, et al. Postswitch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study. Adv Ther. 2022 Nov;39(11):5259-5273. doi: 10.1007/s12325-022-02303-1. Epub 2022 Sep 22.Takeuchi T, Nishikawa K, Yamada F, et al. Realworld safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients na ve to or switched from biologics. Mod Rheumatol. 2022 Jul 1;32(4):718-727. doi: 10.1093/mr/roab068.Takeuchi T, Nishikawa K, Yamada F, et al. Realworld safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients na ve to or switched from biologics. Mod Rheumatol. 2022 Jul 1;32(4):718-727. doi: 10.1093/mr/roab068.Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.Melville AR, Yusof Y, Fitton J, et al. Realworld experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2021 Aug 2;60(8):3679-3688. doi: 10.1093/rheumatology/keaa834.Melville AR, Yusof Y, Fitton J, et al. Realworld experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2021 Aug 2;60(8):3679-3688. doi: 10.1093/rheumatology/keaa834.Kawashiri SY, Shimizu T, Sato S, et al. Switching from originator infliximab to infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments. Medicine (Baltimore). 2020 Jul 24;99(30):e21151. doi: 10.1097/MD.0000000000021151.Kawashiri SY, Shimizu T, Sato S, et al. Switching from originator infliximab to infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments. Medicine (Baltimore). 2020 Jul 24;99(30):e21151. doi: 10.1097/MD.0000000000021151.Cantini F, Benucci M. Focus on biosimilar etanercept – bioequivalence and interchangeability. Biologics. 2018 Aug 30:12: 87-95. doi: 10.2147/BTT.S126854. eCollection 2018.Cantini F, Benucci M. Focus on biosimilar etanercept – bioequivalence and interchangeability. Biologics. 2018 Aug 30:12: 87-95. doi: 10.2147/BTT.S126854. eCollection 2018.Brouwer R, Kloster PMT, Masselink JB, Vonkeman HE. Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients. Pharmacol Res Perspect. 2022 Dec;10(6):e01025. doi: 10.1002/prp2.1025.Brouwer R, Kloster PMT, Masselink JB, Vonkeman HE. Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients. Pharmacol Res Perspect. 2022 Dec;10(6):e01025. doi: 10.1002/prp2.1025.Scrivo R, Castellani C, Manusco S, et al. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clin Exp Rheumatol. 2023 Mar;41(3):613-619. doi: 10.55563/clinexprheumatol/bf00j9. Epub 2022 Jul 28.Scrivo R, Castellani C, Manusco S, et al. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clin Exp Rheumatol. 2023 Mar;41(3):613-619. doi: 10.55563/clinexprheumatol/bf00j9. Epub 2022 Jul 28.Atzeni F, Gerratana E, Bongiovanni S, et al. Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. Isr Med Assoc J. 2021 Jun;23(6):344-349.Atzeni F, Gerratana E, Bongiovanni S, et al. Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. Isr Med Assoc J. 2021 Jun;23(6):344-349.Losinska K, Korkosz M, Pripp AH, Haugeberg G. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naпve to or switched from reference rituximab. Rheumatol Int. 2023 May;43(5):881-888. doi: 10.1007/s00296-023-05307-4. Epub 2023 Mar 16.Losinska K, Korkosz M, Pripp AH, Haugeberg G. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naпve to or switched from reference rituximab. Rheumatol Int. 2023 May;43(5):881-888. doi: 10.1007/s00296-023-05307-4. Epub 2023 Mar 16.Avouac J, Moltу A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018 Apr;47(5):741-748. doi: 10.1016/j.semarthrit. 2017.10.002. Epub 2017 Oct 5.Avouac J, Moltу A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Semin Arthritis Rheum. 2018 Apr;47(5):741-748. doi: 10.1016/j.semarthrit.2017.10.002. Epub 2017 Oct 5.Ascef BO, Matheus O. Almeida MO, et al. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta analysis. Sci Rep. 2023 Aug 22;13(1):13699. doi: 10.1038/s41598-023-40222-5.Ascef BO, Matheus O. Almeida MO, et al. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta analysis. Sci Rep. 2023 Aug 22;13(1):13699. doi: 10.1038/s41598-023-40222-5.Kim JW, Jung JY, Suh CH. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin Biol Ther. 2021 Jan; 21(1):57-73. doi: 10.1080/14712598.2020.1812575. Epub 2020 Oct 16.Kim JW, Jung JY, Suh CH. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opin Biol Ther. 2021 Jan; 21(1):57-73. doi: 10.1080/14712598.2020.1812575. Epub 2020 Oct 16.Chingcuanco F, Segal JB, Kim SC, et al. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review. Ann Intern Med. 2016 Oct 18;165(8):565-574. doi: 10.7326/M16-0428. Epub 2016 Aug 2.Chingcuanco F, Segal JB, Kim SC, et al. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review. Ann Intern Med. 2016 Oct 18;165(8):565-574. doi: 10.7326/M16-0428. Epub 2016 Aug 2.Moots RJ, Curiale C, Petersel D, et al. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. BioDrugs. 2018 Jun; 32(3):193-199. doi: 10.1007/s40259-018-0283-4.Moots RJ, Curiale C, Petersel D, et al. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. BioDrugs. 2018 Jun; 32(3):193-199. doi: 10.1007/s40259-018-0283-4.Lee YH, Song GG. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. Z Rheumatol. 2023 Apr;82(3):248-255. doi: 10.1007/s00393-021-01041-z. Epub 2021 Jul 5.Lee YH, Song GG. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. Z Rheumatol. 2023 Apr;82(3):248-255. doi: 10.1007/s00393-021-01041-z. Epub 2021 Jul 5.Komaki Y, Yamada A, Komaki F, et al. Efficacy, safety and pharmokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May:79:4-16. doi: 10.1016/j.jaut.2017.02.003. Epub 2017 Feb 13.Komaki Y, Yamada A, Komaki F, et al. Efficacy, safety and pharmokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May:79:4-16. doi: 10.1016/j.jaut.2017.02.003. Epub 2017 Feb 13.Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen2019-000900. eCollection 2019.Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen2019-000900. eCollection 2019.Kulikov AY, Serpik VG, Lila AM. Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022:16(S3):1- 17. (In Russ.). doi: 10.14412/1996-7012-2022-2S-1-17.Kulikov AY, Serpik VG, Lila AM. Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022:16(S3):1- 17. (In Russ.). doi: 10.14412/1996-7012-2022-2S-1-17.Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016 Jul;44(4):257-266. doi: 10.1016/j.biologicals.2016.03.006. Epub 2016 Apr 23.Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016 Jul;44(4):257-266. doi: 10.1016/j.biologicals.2016.03.006. Epub 2016 Apr 23.Nasonov EL. Biosimilars n rheumatology. Nauchno-prakticheskaya revmatologiya. 2016; 54(6):628-640. (In Russ.).Nasonov EL. Biosimilars n rheumatology. Nauchno-prakticheskaya revmatologiya. 2016; 54(6):628-640. (In Russ.).

The authors declare that there are no conflicts of interest present.